Dyne Therapeutics, Inc. DYN Debt-to-equity

Debt-to-equity at other companies

Sarepta Therapeutics, Inc.SRPT

0.1×0.0×

Ionis PharmaceuticalsIONS

0.6×-0.7×

Arrowhead ResearchARWR

0.2×0.0×

Wave Life SciencesWVE

0.1×-0.1×

Solid Biosciences Inc.SLDB

0.1×0.0×

Edgewise Therapeutics, Inc.EWTX

0×0.0×

FAQ

What is Dyne Therapeutics, Inc.'s debt-to-equity?

Dyne Therapeutics, Inc. (DYN) reported debt-to-equity of 0.2× in Q1 2026.

How has Dyne Therapeutics, Inc.'s debt-to-equity changed year-over-year?

Dyne Therapeutics, Inc.'s debt-to-equity increased by 458.7% year-over-year, from 0× to 0.2×.

What is the long-term trend for Dyne Therapeutics, Inc.'s debt-to-equity?

Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s debt-to-equity has grown at a 137.6% compound annual growth rate (CAGR), from 0× to 0.2×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.